Skip to main content

Advertisement

Table 7 Main and secondary outcomes for medicine groups at twelve week follow up

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable Mebeverine Methylcellulose Placebo Significance
IBS-SSS total mean (n = 123) 203.1(181.3- 223.0) 205.4 (185.3 -225.5) 210.9 (191.1 - 230.7) p = 0.865
IBS-QOL score (n = 123) 68.9 (64.1 – 73.6) 66.3 (61.9 – 70.8) 70.2 (65.9 – 74.6) P = 0.453
HADS score for anxiety (n = 114) 8.2 (7.3 – 9.1) 8.7 (7.9- 9.6) 9.0 (8.2 -9.8) p = 0.422
HADS score for depression (n = 114) (%)     P = 0.655
Normal (0–7) 25 (78.1) 35 (89.7) 33 (76.7)  
Mild (8–10) 5 (15.6) 2 (5.1) 7 (16.3)  
Moderate or Severe (11–21) 2 (6.3) 2 (5.1) 3 (7.0)  
Enablement score (n = 113)     P = 0.231
0 6 (19.4) 14 (35.9) 12 (27.9)  
1-2 5 (16.1) 6 (15.4) 5 (11.6)  
3-5 9 (29.0) 11 (28.2) 15 (34.9)  
6-12 11 (35.5) 8 (20.5) 11(25.6)  
SGA (%)     
Responders 16 (57.1) 17 (43.6) 19 (44.2) P = 0.538
Non responders 12 (42.9) 22 (56.4) 24 (55.8)  
  1. ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression, Enablement and SGA (n (%).